West Pharmaceutical Raises 2026 Profit Outlook To $9.38-$9.48 A Share As High-Value Components Jump 19.7%

West lifted its full-year sales and adjusted earnings guidance after third-quarter sales rose 8.7% to $874.5 million.

Share
West Pharmaceutical Raises 2026 Profit Outlook To $9.38-$9.48 A Share As High-Value Components Jump 19.7%

West Pharmaceutical Services, which makes containment and delivery systems for injectable drugs, raised its 2026 guidance for adjusted earnings to $9.38-$9.48 a share, up from $8.85-$9.05, after third-quarter results that CEO Michel Lagarde said exceeded the company's expectations. Net sales guidance rose to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion.

Components lead the quarter

Third-quarter net sales reached $874.5 million, up 8.7% from a year earlier and 11.9% organically. Diluted earnings per share rose 57.3% to $3.02, and adjusted earnings per share climbed 35.7% to $2.66.

Net income of $214.0 million included a $55.7 million gain on selling the SmartDose 3.5mL on-body delivery system to AbbVie, so the reported figure runs ahead of the underlying trend. Adjusted operating margin widened to 25.3% from 21.1%.

"Our results were again led by our High-Value Product (HVP) Components business," Lagarde said. That line grew 19.7% to $466.7 million and made up 53% of sales. Delivery devices were flat at $99.1 million, and standard products rose 2.9% to $163.0 million.

The West Vantage segment fell 7.3% to $145.7 million, which the company tied to the planned loss of a continuous glucose monitor customer. Management said that result was slightly better than expected.

Buybacks and cash

West repurchased $231 million of stock in the quarter, bringing its total for the first nine months to $685 million. Operating cash flow for the nine months was $403 million, with capital spending of $125 million. Full-year capital spending guidance was cut to $215 million-$220 million from $250 million-$275 million.

The board also declared a fourth-quarter dividend of $0.26 a share, 18% above the $0.22 paid in the prior quarter.

The business behind the numbers

West makes stoppers, seals, syringe and cartridge components, vials and self-injection devices for drug companies. Its Proprietary Products segment, which sells mainly to drugmakers, generated $728.8 million of third-quarter sales, up 12.6%.

For the fourth quarter, West guides to net sales of $820 million-$830 million and adjusted earnings per share of $2.22-$2.32, according to its earnings presentation. Organic sales growth guidance for the full year rose to 11.3%-11.6% from 10%-11%.

West expects no further SmartDose 3.5mL product sales for the rest of the year, after $11.8 million in the third quarter.

Sources

More on West Pharmaceutical

All West Pharmaceutical (WST) coverage →